Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
Therapeutic Advances in Medical Oncology
|
February 6, 2023
Targeting lipid metabolism in metastatic prostate cancer
Tahlia Scheinberg, Blossom Mak, Lisa Butler, et al.
Asia-Pacific Journal of Clinical Oncology
|
January 31, 2022
Evaluation of a mainstream genetic testing program for women with ovarian or breast cancer
Emilia Ip, Alison Luk Young, Tahlia Scheinberg, et al.
Asia-Pacific Journal of Clinical Oncology
|
November 21, 2023
An Australian mainstream genetic testing program: Clinicians views about current and future practices
Alison Luk Young, Emilia Ip, Tahlia Scheinberg, et al.
Asia-Pacific Journal of Clinical Oncology
|
April 21, 2020
Mainstream consent programs for genetic counseling in cancer patients: A systematic review
Tahlia Scheinberg, Alison Young, Henry Woo, et al.
Therapeutic Advances in Medical Oncology
|
July 7, 2025
Immunotherapy in metastatic prostate cancer
Liam Dwyer, Claudia Leslie, Rhiannon Mellor, et al.
Cancer Reports (Hoboken, N.J.)
|
December 14, 2020
PD-1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma
Tahlia Scheinberg, Anna Lomax, Martin Tattersall, et al.
Therapeutic Advances in Medical Oncology
|
December 18, 2024
Evolocumab in metastatic castration-resistant prostate cancer: study protocol for a single-arm, phase II trial, and initial experience with use of a validated lipid biomarker to direct therapy
Rhiannon Mellor, Luke Ardolino, Tahlia Scheinberg, et al.
Journal of Medical Genetics
|
October 26, 2021
Catastrophic chemotherapy toxicity leading to diagnosis of Fanconi anaemia due to <i>FANCD1/BRCA2</i> during adulthood: description of an emerging phenotype
Emilia Ip, Catriona McNeil, Peter Grimison, et al.
Prostate Cancer and Prostatic Diseases
|
May 5, 2023
PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer
Tahlia Scheinberg, Hui-Ming Lin, Michael Fitzpatrick, et al.
BMJ Open
|
January 29, 2020
Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)
Tahlia Scheinberg, James Kench, Martin Stockler, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
Therapeutic Advances in Medical Oncology
|
February 6, 2023
Targeting lipid metabolism in metastatic prostate cancer
Tahlia Scheinberg, Blossom Mak, Lisa Butler, et al.
Asia-Pacific Journal of Clinical Oncology
|
January 31, 2022
Evaluation of a mainstream genetic testing program for women with ovarian or breast cancer
Emilia Ip, Alison Luk Young, Tahlia Scheinberg, et al.
Asia-Pacific Journal of Clinical Oncology
|
November 21, 2023
An Australian mainstream genetic testing program: Clinicians views about current and future practices
Alison Luk Young, Emilia Ip, Tahlia Scheinberg, et al.
Asia-Pacific Journal of Clinical Oncology
|
April 21, 2020
Mainstream consent programs for genetic counseling in cancer patients: A systematic review
Tahlia Scheinberg, Alison Young, Henry Woo, et al.
Therapeutic Advances in Medical Oncology
|
July 7, 2025
Immunotherapy in metastatic prostate cancer
Liam Dwyer, Claudia Leslie, Rhiannon Mellor, et al.
Cancer Reports (Hoboken, N.J.)
|
December 14, 2020
PD-1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma
Tahlia Scheinberg, Anna Lomax, Martin Tattersall, et al.
Therapeutic Advances in Medical Oncology
|
December 18, 2024
Evolocumab in metastatic castration-resistant prostate cancer: study protocol for a single-arm, phase II trial, and initial experience with use of a validated lipid biomarker to direct therapy
Rhiannon Mellor, Luke Ardolino, Tahlia Scheinberg, et al.
Journal of Medical Genetics
|
October 26, 2021
Catastrophic chemotherapy toxicity leading to diagnosis of Fanconi anaemia due to <i>FANCD1/BRCA2</i> during adulthood: description of an emerging phenotype
Emilia Ip, Catriona McNeil, Peter Grimison, et al.
Prostate Cancer and Prostatic Diseases
|
May 5, 2023
PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer
Tahlia Scheinberg, Hui-Ming Lin, Michael Fitzpatrick, et al.
BMJ Open
|
January 29, 2020
Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)
Tahlia Scheinberg, James Kench, Martin Stockler, et al.
Page
of 2